137 related articles for article (PubMed ID: 35470751)
1. Effectiveness of oral etoposide in recurrent or refractory epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.
Kongsawatvorakul C; Charakorn C; Chittithaworn S; Lertkhachonsuk AA
J Obstet Gynaecol; 2022 Aug; 42(6):2331-2335. PubMed ID: 35470751
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of sequential chemotherapy efficacy in ovarian epithelial carcinoma, fallopian tube carcinoma and primary peritoneal carcinoma].
Shen XY; Li XP; Wang Y; Wu Y; Li Y; Yang YC; Wei LH; Fan Y; Tang ZQ
Zhonghua Fu Chan Ke Za Zhi; 2024 May; 59(5):383-390. PubMed ID: 38797568
[No Abstract] [Full Text] [Related]
3. Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer.
Bozkaya Y; Doğan M; Umut Erdem G; Tulunay G; Uncu H; Arık Z; Demirci U; Yazıcı O; Zengin N
J Obstet Gynaecol; 2017 Jul; 37(5):649-654. PubMed ID: 28325092
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study.
Tatsuki S; Shoji T; Abe M; Tomabechi H; Takatori E; Kaido Y; Nagasawa T; Kagabu M; Aida T; Baba T
Anticancer Res; 2022 Sep; 42(9):4603-4610. PubMed ID: 36039449
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.
Nishio S; Katsumata N; Matsumoto K; Tanabe H; Yonemori K; Kouno T; Shimizu C; Ando M; Kamura T; Kasamatsu T; Fujiwara Y
J Cancer Res Clin Oncol; 2009 Apr; 135(4):551-7. PubMed ID: 18830625
[TBL] [Abstract][Full Text] [Related]
6. Outcomes and Prognostic Factors of Patients with Platinum- Resistant or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer.
Hamontri S; Tantitamit T
Asian Pac J Cancer Prev; 2023 Apr; 24(4):1401-1405. PubMed ID: 37116164
[TBL] [Abstract][Full Text] [Related]
7. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
8. Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis.
Sharma A; Malik PS; Khurana S; Kumar S; Bhatla N; Ray MD; Kumar L
Indian J Med Res; 2019 Dec; 150(6):575-583. PubMed ID: 32048620
[TBL] [Abstract][Full Text] [Related]
9. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
10. Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study.
Friedlander ML; Stockler M; O'Connell R; Voysey M; Oza A; Gillies K; Donovan H; Martyn J; Sjoquist K; Butow P; King MT;
Int J Gynecol Cancer; 2014 Jun; 24(5):857-64. PubMed ID: 24844219
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
Sharma A; Singh M; Chauhan R; Malik PS; Khurana S; Mathur S; Kumar S; Sreenivas V; Kumar L
Gynecol Oncol; 2021 Aug; 162(2):382-388. PubMed ID: 34088513
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
13. Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study).
Shoji T; Takatori E; Nagasawa T; Kagabu M; Baba T; Shigeto T; Matsumura Y; Shimizu D; Terada Y; Seino M; Ohta T; Nagase S; Shigeta S; Tokunaga H; Shimada M; Kaiho-Sakuma M; Furukawa S; Soeda S; Watanabe T; Takahashi F; Yokoyama Y
Int J Clin Oncol; 2022 Dec; 27(12):1874-1880. PubMed ID: 36214925
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
Selle F; Sevin E; Ray-Coquard I; Mari V; Berton-Rigaud D; Favier L; Fabbro M; Lesoin A; Lortholary A; Pujade-Lauraine E
Ann Oncol; 2014 Nov; 25(11):2191-2196. PubMed ID: 25210017
[TBL] [Abstract][Full Text] [Related]
15. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study.
Lan CY; Wang Y; Xiong Y; Li JD; Shen JX; Li YF; Zheng M; Zhang YN; Feng YL; Liu Q; Huang HQ; Huang X
Lancet Oncol; 2018 Sep; 19(9):1239-1246. PubMed ID: 30082170
[TBL] [Abstract][Full Text] [Related]
16. Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology.
Kucukoner M; Isikdogan A; Yaman S; Gumusay O; Unal O; Ulas A; Elkiran ET; Kaplan MA; Ozdemir N; Inal A; Urakci Z; Buyukberber S
Asian Pac J Cancer Prev; 2012; 13(8):3973-6. PubMed ID: 23098502
[TBL] [Abstract][Full Text] [Related]
17. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
[TBL] [Abstract][Full Text] [Related]
18. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
19. Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer.
Cohen S; Schwartz M; Dottino P; Beddoe AM
J Ovarian Res; 2019 Apr; 12(1):36. PubMed ID: 31027500
[TBL] [Abstract][Full Text] [Related]
20. Continuous oral cyclophosphamide as salvage or maintenance therapy in ovarian, primary peritoneal, and fallopian tube cancers: A retrospective, single institute study.
Wong CN; Wong CN; Liu FS
Taiwan J Obstet Gynecol; 2017 Jun; 56(3):302-305. PubMed ID: 28600037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]